Europe - BIT:1EVT - DE0005664809 - Common Stock
The current stock price of 1EVT.MI is 6.038 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TN8.DE | THERMO FISHER SCIENTIFIC INC | 24.41 | 172.00B | ||
DAP.DE | DANAHER CORP | 28.82 | 132.47B | ||
1DHR.MI | DANAHER CORP | 28.66 | 131.68B | ||
LO3.DE | LONZA GROUP AG-REG | 35.74 | 41.65B | ||
QTS.DE | IQVIA HOLDINGS INC | 17.93 | 29.81B | ||
DIM.PA | SARTORIUS STEDIM BIOTECH | 48.03 | 19.31B | ||
56S1.DE | SARTORIUS STEDIM BIOTECH | 47.26 | 19.00B | ||
SRT3.DE | SARTORIUS AG-VORZUG | 51.98 | 16.93B | ||
SRT.DE | SARTORIUS AG | 42.39 | 13.81B | ||
ILU.DE | ILLUMINA INC | 24.02 | 13.11B | ||
ERF.PA | EUROFINS SCIENTIFIC | 17.26 | 11.32B | ||
ESF0.DE | EUROFINS SCIENTIFIC | 17.25 | 11.31B |
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,759 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
EVOTEC SE
Essener Bogen 7
Hamburg HAMBURG DE
Employees: 4759
Phone: 4940560810
The current stock price of 1EVT.MI is 6.038 EUR. The price decreased by -3.45% in the last trading session.
The exchange symbol of EVOTEC SE is 1EVT and it is listed on the Euronext Milan exchange.
1EVT.MI stock is listed on the Euronext Milan exchange.
12 analysts have analysed 1EVT.MI and the average price target is 9.47 EUR. This implies a price increase of 56.86% is expected in the next year compared to the current price of 6.038. Check the EVOTEC SE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EVOTEC SE (1EVT.MI) has a market capitalization of 2.14B EUR. This makes 1EVT.MI a Mid Cap stock.
EVOTEC SE (1EVT.MI) currently has 4759 employees.
The Revenue of EVOTEC SE (1EVT.MI) is expected to decline by -1.21% in the next year. Check the estimates tab for more information on the 1EVT.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
1EVT.MI does not pay a dividend.
EVOTEC SE (1EVT.MI) will report earnings on 2025-11-05, before the market open.
EVOTEC SE (1EVT.MI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.11).
ChartMill assigns a technical rating of 3 / 10 to 1EVT.MI.
ChartMill assigns a fundamental rating of 2 / 10 to 1EVT.MI. 1EVT.MI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months 1EVT.MI reported a non-GAAP Earnings per Share(EPS) of -1.11. The EPS decreased by -136.17% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -8.6% | ||
ROE | -18.39% | ||
Debt/Equity | 0.42 |
12 analysts have analysed 1EVT.MI and the average price target is 9.47 EUR. This implies a price increase of 56.86% is expected in the next year compared to the current price of 6.038.
For the next year, analysts expect an EPS growth of 57.39% and a revenue growth -1.21% for 1EVT.MI